Strategic Acquisition The recent acquisition of ILS Automation by DCI Inc. indicates a strategic move to expand capabilities in bioprocess control solutions, presenting opportunities to offer tailored automation systems for biopharmaceutical and bioprocess industries.

Industry Recognition Receiving the gold Ignition Firebrand Award at ICC 2015 highlights the company's innovation and leadership in SCADA technology, making it a compelling partner for customers seeking state-of-the-art automation solutions.

Product Innovation The launch of AFC 928 Dual Bioreactor Control System demonstrates ILS's commitment to advancing bioprocess control technology, offering potential upsell or cross-sell opportunities with laboratories and biotech firms in need of customized automation hardware.

Niche Expertise ILS Automation's specialization in integrating laboratory systems with SCADA software positions it well to serve process industries like chemical and biotech sectors, offering tailored automation services in these growing markets.

Market Position Operating with a revenue range of 1 to 10 million, ILS is a mid-sized firm with room for growth; targeting similarly scaled companies and leveraging industry awards and recent product launches can help expand their client base in automation projects.